Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600Emelanoma

OncoImmunology

Volumn 5, Issue 3, 2016, Pages

  Ngiow, Shin Foong ^a,b   Meeth, Katrina M ^c   Stannard, Kimberley ^a   Barkauskas, Deborah S ^a   Bollag, Gideon ^d   Bosenberg, Marcus ^c   Smyth, Mark J ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PLEXXIKON INC   (United States)

Author keywords

BRAF inhibitor; BRAFV600E; CSF1R; M2 macrophage; melanoma; PLX3397; PLX4720; tumor

Indexed keywords

B RAF KINASE INHIBITOR; COLONY STIMULATING FACTOR RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN10; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PLX 3397; PROTEIN TYROSINE KINASE INHIBITOR; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VEMURAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAF ONCOGENE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; MALE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOGENE; PD1 PDL1 PATHWAY; PHASE 1 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL INOCULATION;

EID: 84961619711     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1089381     Document Type: Article

References (45)

1. P.B.Chapman, A.Hauschild, C.Robert, J.B.Haanen, P.Ascierto, J.Larkin, R.Dummer, C.Garbe, A.Testori, M.Maio et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med 2011; 364:2507; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
2. G.S.Falchook, G.V.Long, R.Kurzrock, K.B.Kim, T.H.Arkenau, M.P.Brown, O.Hamid, J.R.Infante, M.Millward, A.C.Pavlick et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379:1893; PMID:22608338; http://dx.doi.org/10.1016/S0140-6736(12)60398-5
3. K.T.Flaherty, I.Puzanov, K.B.Kim, A.Ribas, G.A.McArthur, J.A.Sosman, P.J.O'Dwyer, R.J.Lee, J.F.Grippo, K.Nolop et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Eng J Med 2010; 363:809; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011
4. J.A.Sosman, K.B.Kim, L.Schuchter, R.Gonzalez, A.C.Pavlick, J.S.Weber, G.A.McArthur, T.E.Hutson, S.J.Moschos, K.T.Flaherty et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Eng J Med 2012; 366:707; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302
5. E.Hartsough, Y.Shao, A.E.Aplin. Resistance to RAF inhibitors revisited. J Invest Dermatol 2014; 134:319; PMID:24108405; http://dx.doi.org/10.1038/jid.2013.358
6. M.Holderfield, M.M.Deuker, F.McCormick, M.McMahon. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nature Reviews. Cancer 2014; 14:455; PMID:24957944; http://dx.doi.org/10.1038/nrc3760
7. P.Lito, N.Rosen, D.B.Solit. Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013; 19:1401; PMID:24202393; http://dx.doi.org/10.1038/nm.3392
8. A.C.Obenauf, Y.Zou, A.L.Ji, S.Vanharanta, W.Shu, H.Shi, X.Kong, M.C.Bosenberg, T.Wiesner, N.Rosen et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 2015; 520:368; PMID:25807485; http://dx.doi.org/10.1038/nature14336
9. C.Sun, L.Wang, S.Huang, G.J.Heynen, A.Prahallad, C.Robert, J.Haanen, C.Blank, J.Wesseling, S.M.Willems et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014; 508:118; PMID:24670642; http://dx.doi.org/10.1038/nature13121
10. Z.A.Cooper, V.R.Juneja, P.T.Sage, D.T.Frederick, A.Piris, D.Mitra, J.A.Lo, F.S.Hodi, G.J.Freeman, M.W.Bosenberg et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014; 2:643; PMID:24903021; http://dx.doi.org/10.1158/2326-6066.CIR-13-0215
11. D.T.Frederick, A.Piris, A.P.Cogdill, Z.A.Cooper, C.Lezcano, C.R.Ferrone, D.Mitra, A.Boni, L.P.Newton, C.Liu et al. BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clin Cancer Res 2013; 19:1225; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630
12. M.P.Smith, B.Sanchez-Laorden, K.O'Brien, H.Brunton, J.Ferguson, H.Young, N.Dhomen, K.T.Flaherty, D.T.Frederick, Z.A.Cooper et al. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov 2014; 4:1214; PMID:25256614; http://dx.doi.org/10.1158/2159-8290.CD-13-1007
13. N.Acquavella, D.Clever, Z.Yu, M.Roelke-Parker, D.C.Palmer, L.Xi, H.Pflicke, Y.Ji, A.Gros, K.Hanada et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res 2015; 3:37; PMID:25358764; http://dx.doi.org/10.1158/2326-6066.CIR-14-0122
14. D.A.Knight, S.F.Ngiow, M.Li, T.Parmenter, S.Mok, A.Cass, N.M.Haynes, K.Kinross, H.Yagita, R.C.Koya et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013; 123:1371; PMID:23454771; http://dx.doi.org/10.1172/JCI66236
15. R.C.Koya, S.Mok, N.Otte, K.J.Blacketor, B.Comin-Anduix, P.C.Tumeh, A.Minasyan, N.A.Graham, T.G.Graeber, T.Chodon et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res 2012; 72:3928; PMID:22693252; http://dx.doi.org/10.1158/0008-5472.CAN-11-2837
16. D.I.Gabrilovich, S.Nagaraj. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162; PMID:19197294; http://dx.doi.org/10.1038/nri2506
17. E.R.Stanley, V.Chitu. CSF-1 receptor signaling in myeloid cells. Cold Spring Harbor Perspect Biol 2014; 6:a021857; PMID:24890514; http://dx.doi.org/10.1101/cshperspect.a021857
18. S.K.Biswas, P.Allavena, A.Mantovani. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Seminars Immunopathol 2013; 35:585; PMID:23657835; http://dx.doi.org/10.1007/s00281-013-0367-7
19. A.Mantovani, P.Allavena. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015; 212:435; PMID:25753580; http://dx.doi.org/10.1084/jem.20150295
20. D.G.DeNardo, D.J.Brennan, E.Rexhepaj, B.Ruffell, S.L.Shiao, S.F.Madden, W.M.Gallagher, N.Wadhwani, S.D.Keil, S.A.Junaid et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011; 1:54; PMID:22039576; http://dx.doi.org/10.1158/2159-8274.CD-10-0028
21. J.B.Mitchem, D.J.Brennan, B.L.Knolhoff, B.A.Belt, Y.Zhu, D.E.Sanford, L.Belaygorod, D.Carpenter, L.Collins, D.Piwnica-Worms et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013; 73:1128; PMID:23221383; http://dx.doi.org/10.1158/0008-5472.CAN-12-2731
22. S.Mok, R.C.Koya, C.Tsui, J.Xu, L.Robert, L.Wu, T.G.Graeber, B.L.West, G.Bollag, A.Ribas. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014; 74:153; PMID:24247719; http://dx.doi.org/10.1158/0008-5472.CAN-13-1816
23. S.M.Pyonteck, L.Akkari, A.J.Schuhmacher, R.L.Bowman, L.Sevenich, D.F.Quail, O.C.Olson, M.L.Quick, J.T.Huse, V.Teijeiro et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19:1264; PMID:24056773; http://dx.doi.org/10.1038/nm.3337
24. C.H.Ries, M.A.Cannarile, S.Hoves, J.Benz, K.Wartha, V.Runza, F.Rey-Giraud, L.P.Pradel, F.Feuerhake, I.Klaman et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014; 25:846; PMID:24898549; http://dx.doi.org/10.1016/j.ccr.2014.05.016
25. D.C.Strachan, B.Ruffell, Y.Oei, M.J.Bissell, L.M.Coussens, N.Pryer, D.Daniel. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2013; 2:e26968; PMID:24498562; http://dx.doi.org/10.4161/onci.26968
26. T.C.van der Sluis, M.Sluijter, S.van Duikeren, B.L.West, C.J.Melief, R.Arens, S.H.van der Burg, T.van Hall. Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression. Cancer Immunol Res 2015; 3(9):1042-51; PMID:25888578; http://dx.doi.org/10.1158/2326-6066.
27. J.Xu, J.Escamilla, S.Mok, J.David, S.Priceman, B.West, G.Bollag, W.McBride, L.Wu. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res 2013; 73:2782; PMID:23418320; http://dx.doi.org/10.1158/0008-5472.CAN-12-3981
28. Y.Zhu, B.L.Knolhoff, M.A.Meyer, T.M.Nywening, B.L.West, J.Luo, A.Wang-Gillam, S.P.Goedegebuure, D.C.Linehan, D.G.DeNardo. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014; 74:5057; PMID:25082815; http://dx.doi.org/10.1158/0008-5472.CAN-13-3723
29. P.C.Ho, K.M.Meeth, Y.C.Tsui, B.Srivastava, M.W.Bosenberg, S.M.Kaech. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNgamma. Cancer Res 2014; 74:3205; PMID:24736544; http://dx.doi.org/10.1158/0008-5472.CAN-13-3461
30. S.M.Steinberg, P.Zhang, B.T.Malik, A.Boni, T.B.Shabaneh, K.T.Byrne, D.W.Mullins, C.E.Brinckerhoff, M.S.Ernstoff, M.W.Bosenberg, M.J.Turk. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunol Res 2014; 2:1044; PMID:25183499; http://dx.doi.org/10.1158/2326-6066.CIR-14-0074
31. A.Mantovani, S.Sozzani, M.Locati, P.Allavena, A.Sica. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunol 2002; 23:549; PMID:12401408; http://dx.doi.org/10.1016/S1471-4906(02)02302-5
32. C.H.June, S.R.Riddell, T.N.Schumacher. Adoptive cellular therapy: a race to the finish line. Science Trans Med 2015; 7:280ps7; PMID:25810311; http://dx.doi.org/10.1126/scitranslmed.aaa3643
33. D.B.Page, M.A.Postow, M.K.Callahan, J.P.Allison, J.D.Wolchok. Immune modulation in cancer with antibodies. Annual Rev Med 2014; 65:185; PMID:24188664; http://dx.doi.org/10.1146/annurev-med-092012-112807
34. R.Pelayo, R.Welner, S.S.Perry, J.Huang, Y.Baba, T.Yokota, P.W.Kincade. Lymphoid progenitors and primary routes to becoming cells of the immune system. Curr Opin Immunol 2005; 17:100; PMID:15766667; http://dx.doi.org/10.1016/j.coi.2005.01.012
35. M.Terme, E.Ullrich, L.Aymeric, K.Meinhardt, J.D.Coudert, M.Desbois, F.Ghiringhelli, S.Viaud, B.Ryffel, H.Yagita et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res 2012; 72:2757; PMID:22427351; http://dx.doi.org/10.1158/0008-5472.CAN-11-3379
36. M.K.Callahan, G.Masters, C.A.Pratilas, C.Ariyan, J.Katz, S.Kitano, V.Russell, R.A.Gordon, S.Vyas, J.Yuan et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res 2014; 2:70; PMID:24416731; http://dx.doi.org/10.1158/2326-6066.CIR-13-0160
37. L.Ferrari de Andrade, S.F.Ngiow, K.Stannard, S.Rusakiewicz, M.Kalimutho, K.K.Khanna, S.K.Tey, K.Takeda, L.Zitvogel, L.Martinet et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res 2014; 74:7298; PMID:25351955; http://dx.doi.org/10.1158/0008-5472.CAN-14-1339
38. S.Mok, J.Tsoi, R.C.Koya, S.Hu-Lieskovan, B.L.West, G.Bollag, T.G.Graeber, A.Ribas. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer 2015; 15:356; PMID:25939769; http://dx.doi.org/10.1186/s12885-015-1377-8
39. J.M.Taube, R.A.Anders, G.D.Young, H.Xu, R.Sharma, T.L.McMiller, S.Chen, A.P.Klein, D.M.Pardoll, S.L.Topalian, L.Chen. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science Translational Med 2012; 4:127ra37; PMID:22461641; http://dx.doi.org/10.1126/scitranslmed.3003689
40. M.W.Teng, S.F.Ngiow, A.Ribas, M.J.Smyth. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Research 2015; 75:2139; PMID:25977340; http://dx.doi.org/10.1158/0008-5472.CAN-15-0255
41. D.Dankort, D.P.Curley, R.A.Cartlidge, B.Nelson, A.N.Karnezis, W.E.Damsky, Jr, M.J.You, R.A.DePinho, M.McMahon, M.Bosenberg. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genetics 2009; 41:544; PMID:19282848; http://dx.doi.org/10.1038/ng.356
42. J.Tsai, J.T.Lee, W.Wang, J.Zhang, H.Cho, S.Mamo, R.Bremer, S.Gillette, J.Kong, N.K.Haass et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008; 105:3041; PMID:18287029; http://dx.doi.org/10.1073/pnas.0711741105
43. W.D.Tap, Z.A.Wainberg, S.P.Anthony, P.N.Ibrahim, C.Zhang, J.H.Healey, B.Chmielowski, A.P.Staddon, A.L.Cohn, G.I.Shapiro et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Eng J Med 2015; 373:428; PMID:26222558; http://dx.doi.org/10.1056/NEJMoa1411366
44. W.E.Damsky, D.P.Curley, M.Santhanakrishnan, L.E.Rosenbaum, J.T.Platt, B.E.Gould Rothberg, M.M.Taketo, D.Dankort, D.L.Rimm, M.McMahon, M.Bosenberg. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011; 20:741; PMID:22172720; http://dx.doi.org/10.1016/j.ccr.2011.10.030
45. S.F.Ngiow, B.von Scheidt, H.Akiba, H.Yagita, M.W.L.Teng, M.J.Smyth. Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors. Cancer Res 2011; 71:3540; PMID:21430066; http://dx.doi.org/10.1158/0008-5472.CAN-11-0096